Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease

American Journal of Nephrology

Volumn 38, Issue 2, 2013, Pages 158-167

  Seifert, Michael E ^a,b,e   De Las Fuentes, Lisa ^c,e   Rothstein, Marcos ^d,e   Dietzen, Dennis J ^e   Bierhals, Andrew J ^f   Cheng, Steven C ^d,e   Ross, Will ^d,e   Windus, David ^d,e   Dávila Román, Víctor G ^c,e   Hruska, Keith A ^b,d,e  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c Cardiovascular Imaging and Clinical Research Core Laboratory   (United States)

^d Renal Division   (United States)

^e Department of Pediatrics ^*  (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Chronic kidney disease; Phosphate binders; Randomized controlled trials; Vascular calcification

Indexed keywords

ANTIHYPERTENSIVE AGENT; DICKKOPF 1 PROTEIN; FIBROBLAST GROWTH FACTOR 23; LANTHANUM CARBONATE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; SCLEROSTIN;

ADULT; AGATSTON SCORE; ARTERIAL STIFFNESS; ARTICLE; BONE DENSITY; CAROTID ARTERY; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; FEASIBILITY STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEADACHE; HUMAN; HYPERGLYCEMIA; KIDNEY TUBULE ABSORPTION; MALE; NAUSEA; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PILOT STUDY; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; FEMORAL ARTERY; HYPOPHOSPHATEMIA; MIDDLE AGED; OUTCOME ASSESSMENT; PHOSPHATE URINE LEVEL; PROTEIN BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DOUBLE-BLIND METHOD; FEASIBILITY STUDIES; FEMALE; HOMEOSTASIS; HUMANS; LANTHANUM; MALE; MIDDLE AGED; PHOSPHATES; PHOSPHORUS; PHOSPHORUS, DIETARY; PILOT PROJECTS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TREATMENT OUTCOME; VASCULAR STIFFNESS;

EID: 84883315472     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000353569     Document Type: Article

References (53)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu Cy: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New Engl J Med 2004; 351: 1296-1305.
2. Culleton BF, Larson MG, Wilson PWF, Evans JC, Parfrey PS, Levy D: Cardiovascular disease and mortality in a community based cohort with mild renal insufficiency. Kidney Int 1999; 56: 2214-2219.
3. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32:S112-S119.
4. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047.
5. Foley RN, Murray AM, Li S, Herzog CA, Mc- Bean AM, Eggers PW, Collins AJ: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-495.
6. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in endstage renal disease. Hypertension 2001; 38: 938-942.
7. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in endstage renal diseases: impact on all cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740.
8. Block GA, Hulbert Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
9. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528.
10. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G, Cholesterol and Recurrent Events Trial I: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-2633.
11. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB, Gaziano JM, Vasan RS: Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167: 879-885.
12. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF: Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease. JAMA 2011; 305: 1119-1127.
13. El-Abbadi MM, Pai AS, Leaf EM, Yang HY, Bartley BA, Quan KK, Ingalls CM, Liao HW, Giachelli CM: Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor- 23, and osteopontin. Kidney Int 2009; 75: 1297-1307.
14. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM: Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011; 109: 697-711.
15. Moe SM, Chen NX: Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008; 19: 213-216.
16. Davies MR, Hruska KA: Pathophysiological mechanisms of vascular calcification in endstage renal disease. Kidney Int 2001; 60: 472-479.
17. Mathew S, Lund R, Strebeck F, Tustison KS, Geurs T, Hruska KA: Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 2007; 18: 122-130.
18. Ix JH, de Boer IH, Peralta CA, Adeney KL, Duprez DA, Jenny NS, Siscovick DS, Kestenbaum BR: Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol 2009; 4: 609-615.
19. Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, Kestenbaum BR: Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2009; 20: 381-387.
20. Meng J, Wassel CL, Kestenbaum BR, Collins TC, Criqul MH, Lewis CE, Cummings SR, Ix JH: Serum phosphorus levels and the spectrum of ankle brachial index in older men. The Osteoporotic Fractures in Men (MrOS) study. Am J Epidemiol 2010; 171: 909-916.
21. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434-2439.
22. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G: Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953.
23. Fang Y, Ginsberg C, Sugatani T, Faugere MC, Malluche H, Hruska KA: The early chronic kidney disease-mineral bone disorder (CKDMBD) stimulates vascular calcification. Kidney Int 2013, in press.
24. Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K: Patterns of FGF-23, DMP1 and MEPE expression in patients with chronic kidney disease. Bone 2009; 45: 1161-1168.
25. Sabbagh Y, Graciolli FG, O'Brien S, Tang W, dos Reis LM, Ryan S, Phillips L, Boulanger J, Song W, Bracken C, Liu S, Ledbetter S, Dechow P, Canziani ME, Carvalho AB, Jorgetti V, Moyses RM, Schiavi SC: Repression of osteocyte Wnt/?-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 2012; 27: 1757-1772.
26. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
27. Pauca AL, O'Rourke MF, Kon ND: Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 2001; 38: 932-937.
28. Van Bortel LM, Balkestein EJ, van der Heijden- Spek JJ, Vanmolkot FH, Staessen JA, Kragten JA, Vredeveld JW, Safar ME, Boudier HAS, Hoeks AP: Noninvasive assessment of local arterial pulse pressure: comparison of applanation tonometry and echo-tracking. J Hypertens 2001; 19: 1037-1044.
29. O'Rourke MF, Adji A: An updated clinical primer on large artery mechanics: implications of pulse waveform analysis and arterial tonometry. Curr Opin Cardiol 2005; 20: 275-281.
30. O'Rourke MF, Pauca A, Jiang XJ: Pulse wave analysis. Br J Clin Pharmacol 2001; 51: 507-522.
31. Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, Cockcroft JR, Webb DJ: Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens 1998; 16: 2079-2084.
32. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS, Rembold CM, Post WS: Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008; 21: 93-111.
33. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, Alderman MH: Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992; 20: 1251-1260.
34. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A: Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiography 2009; 10: 165-193.
35. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R: Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827-832.
36. Mathews SJ, de las Fuentes L, Podaralla P, Cabellon A, Zheng S, Bierhals A, Spence K, Slatopolsky E, Davila-Roman VG, Delmez JA: Effects of sodium thiosulfate on vascular calcification in end-stage renal disease: a pilot study of feasibility, safety and efficacy. Am J Nephrol 2011; 33: 131-138.
37. Reference Values for Arterial Stiffness Collaboration: Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J 2010; 31: 2338-2350.
38. KDIGO 2013 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150.
39. Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, Martinez-Calero A, Navas V, Rodriguez M, Ortiz A: Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephrol Dial Transplant 2011; 26: 2567-2571.
40. Hill KM, Martin BR, Wastney ME, McCabe GP, Moe SM, Weaver CM, Peacock M: Oral calcium carbonate affects calcium but not phosphorus balance in stage 34 chronic kidney disease. Kidney Int 2013; 83: 959-966.
41. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM: Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23: 1407-1415.
42. Isakova T, Gutierrez OM, Smith K, Epstein M, Keating LK, Juppner H, Wolf M: Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 2011; 26: 584-591.
43. Block GA, Persky MS, Ketteler M, Kestenbaum B, Thadhani R, Kooienga L, Spiegel D, Asplin J, Ehrlich J, Dennis V, Nissenson A, Chertow GM, Wheeler DC: A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis Int 2009; 13: 360-362.
44. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Mallamaci F, Zoccali C: Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis 2012; 59: 177-185.
45. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moyses RM: Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKDMBD therapy? Clin J Am Soc Nephrol 2010; 5: 286-291.
46. Sigrist M, Tang M, Beaulieu M, Espino-Hernandez G, Er L, Djurdjev O, Levin A: Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial. Nephrol Dial Transplant 2013; 28: 161-169.
47. Isakova T, Barchi-Chung A, Enfield G, Smith K, Vargas G, Houston J, Xie H, Wahl P, Schiavenato E, Dosch A, Gutierrez OM, Diego J, Lenz O, Contreras G, Mendez A, Weiner R, Wolf M: Effects of dietary phosphate restriction and lanthanum carbonate on FGF23 in CKD. J Am Soc Nephrol 2012; 23:P45A.
48. Ix JH, Shlipak MG, Wassel CL, Whooley MA: Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant 2010; 25: 993-997.
49. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu Cy, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378.
50. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, AquillonPrada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408.
51. Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, Kiss I, Rosivall L, Kosa J, Lakatos P, Kovesdy CP, Mucsi I: Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22: 956-966.
52. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA: Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009; 20: 397-404.
53. Grandi NC, Brenner H, Hahmann H, Wusten B, Marz W, Rothenbacher D, Breitling LP: Calcium, phosphate and the risk of cardiovascular events and all-cause mortality in a population with stable coronary heart disease. Heart 2012; 98: 926-933.